Insider Buying: STAAR Surgical (NASDAQ:STAA) Major Shareholder Acquires 31,780 Shares of Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 31,780 shares of the business’s stock in a transaction on Wednesday, April 2nd. The shares were acquired at an average price of $17.43 per share, with a total value of $553,925.40. Following the purchase, the insider now owns 12,487,044 shares of the company’s stock, valued at approximately $217,649,176.92. This trade represents a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, March 31st, Broadwood Partners, L.P. bought 22,189 shares of STAAR Surgical stock. The stock was bought at an average cost of $17.46 per share, with a total value of $387,419.94.
• On Thursday, March 27th, Broadwood Partners, L.P. purchased 3,620 shares of STAAR Surgical stock. The stock was bought at an average price of $17.48 per share, for a total transaction of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. acquired 34,296 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.44 per share, with a total value of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. bought 108,720 shares of STAAR Surgical stock. The stock was purchased at an average cost of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. purchased 93,124 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The shares were purchased at an average cost of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. purchased 259,316 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The stock was acquired at an average price of $15.49 per share, with a total value of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock. The shares were acquired at an average price of $14.96 per share, for a total transaction of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. purchased 8,221 shares of STAAR Surgical stock. The stock was acquired at an average cost of $21.50 per share, with a total value of $176,751.50.

STAAR Surgical Trading Down 8.5 %

NASDAQ STAA opened at $15.92 on Friday. STAAR Surgical has a 12 month low of $13.50 and a 12 month high of $52.68. The stock has a 50-day simple moving average of $18.82 and a 200 day simple moving average of $24.76. The company has a market capitalization of $785.25 million, a PE ratio of -38.83 and a beta of 0.75.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Stifel Nicolaus lowered their price objective on shares of STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, February 12th. Canaccord Genuity Group dropped their price objective on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a research report on Thursday, February 13th. William Blair lowered STAAR Surgical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 12th. Stephens restated an “equal weight” rating and set a $17.00 target price on shares of STAAR Surgical in a research report on Tuesday, March 18th. Finally, Jefferies Financial Group lowered STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $25.29.

Institutional Trading of STAAR Surgical

A number of institutional investors and hedge funds have recently modified their holdings of STAA. Resona Asset Management Co. Ltd. bought a new position in STAAR Surgical during the 4th quarter worth approximately $36,411,000. Vanguard Group Inc. boosted its position in shares of STAAR Surgical by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock worth $142,232,000 after purchasing an additional 319,441 shares in the last quarter. Yunqi Capital Ltd grew its holdings in shares of STAAR Surgical by 48.9% in the 4th quarter. Yunqi Capital Ltd now owns 767,413 shares of the medical instruments supplier’s stock valued at $18,640,000 after buying an additional 252,113 shares during the period. JPMorgan Chase & Co. increased its position in shares of STAAR Surgical by 411.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock valued at $7,978,000 after buying an additional 172,779 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in STAAR Surgical by 25.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 853,370 shares of the medical instruments supplier’s stock worth $20,728,000 after buying an additional 171,046 shares during the period. 96.70% of the stock is owned by institutional investors.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.